#United States #Boston #Curadev Pharma #CRD3874-SI #MSK Cancer Center

Curadev Expands Collaboration with MSK for Innovative Cancer Treatment

In an important step for cancer therapeutics, Curadev Pharma, a clinical-stage biotechnology firm, is deepening its collaboration with Memorial Sloan Kettering Cancer Center (MSK). This partnership will enhance the development of CRD3874-SI, a novel small-molecule allosteric Stimulator of Interferon Genes (STING) agonist, through the MSK Therapeutics Accelerator program.

The announcement marks an exciting milestone as Curadev seeks to advance CRD3874-SI specifically for patients battling advanced or metastatic cancer. The collaboration builds upon a Phase 1a/b clinical trial already in progress at MSK, aimed at examining the drug's effectiveness for patients suffering from sarcoma and Merkel cell carcinoma. However, this expanded partnership intends to extend research into new types of cancer, exploring CRD3874-SI's full therapeutic potential.

Dr. William Tap, Chief of the Sarcoma Medical Oncology Service at MSK, expressed enthusiasm regarding the collaboration, stating, "MSK and its Division of Solid Tumors are excited to co-develop CRD3874-SI, a novel first-in-class allosteric STING agonist." The safety and efficacy of CRD3874-SI have shown positive early results, sparking interest in expanding the clinical research to multiple solid tumor cohorts. With innovative structures like the MSK Accelerator Program facilitating this research, the goal is to expedite the development of novel anti-cancer compounds.

Curadev's CEO, Dr. Arjun Surya, highlighted the potential benefits of their partnership with MSK, which is a recognized leader in cancer immunotherapy development. He mentioned that early indications from initial studies are encouraging and stated, "The research and development collaboration between oncologists at MSK and our team at Curadev could serve as a model for bridging laboratory research to clinical applications."

Curadev's mission centers around discovering and developing new small-molecule therapies that target complex diseases. The company, founded in 2021, focuses its efforts on drug candidates that influence next-generation therapeutic targets. This endeavor highlights Curadev's commitment to advancing patient care through innovative cancer treatments.

The MSK's Therapeutics Accelerator program symbolizes a strategic alliance between leading cancer research institutions and biotechnology firms to facilitate the development of breakthrough cancer treatments. By working closely with clinical and scientific experts, Curadev and MSK aim to harness cutting-edge research methodologies to develop impactful cancer therapeutics.

As clinical trials progress, the collaboration between Curadev and MSK is positioned to potentially change the landscape of cancer treatment, providing patients with revolutionary new options in immunotherapy. Together, they are poised to make significant contributions to the future of cancer care, illustrating how strategic partnerships can result in meaningful advancements in medical science.